 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achilles Therapeutics (NASDAQ:ACHL - Get Free Report) and DBV Technologies (NASDAQ:DBVT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast...

Contrasting Achilles Therapeutics (NASDAQ:ACHL) & DBV Technologies (NASDAQ:DBVT)

Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma Improved VELOS manufacturing process delivering higher cNeT doses Protocols updated...

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Improved VELOS manufacturing process delivering higher cNeT doses Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 First three...

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Achilles Therapeutics price target lowered by $5 at Chardan, here's why

Piper Sandler gets more bearish on Achilles Therapeutics, downgrades shares

IN8bio (NASDAQ:INAB - Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...

Reviewing Achilles Therapeutics (NASDAQ:ACHL) & IN8bio (NASDAQ:INAB)

Achilles Therapeutics plc (NASDAQ:ACHL  Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling...

Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Decrease in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL  Get Free Report) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 10,100 shares, a...

Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Declines By 79.5%

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Achilles Therapeutics plc (NASDAQ:ACHL  Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 49,200 shares, an increase of...

Achilles Therapeutics plc (NASDAQ:ACHL) Sees Significant Increase in Short Interest

Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.

Volume (M)	184,532.00
52-Wk High	$1.76
52-Wk Low	$0.7402

ACHL Achilles Therapeutics Plc - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals